BioSpace News Archive

- First-of-its-kind clinical trial in children and adolescents with fibrosing interstitial lung disease (ILD) initiated globally - This new study builds on the Phase III INBUILD® trial and approval of Ofev® in adult patients with fibrosing ILDs with a progressive phenotype - Global Phase III multicenter clinical trial is planned to be conducted in approximately 70 sites in 24 countries, including the United States [1

Vaccibody AS and Nektar Therapeutics announced that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin, Nektar’s CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibody’s personalized neoantigen cancer vaccine, in patients with advanced squamous cell carcinoma of the head and neck.

Omega Therapeutics™, a company pioneering a new category of genomic medicine through epigenomic programming, today announced the appointment of Dr. Roger Sawhney as Chief Financial Officer. Dr. Sawhney brings 25 years of financial and strategic expertise to Omega, with vast experience ranging from global investments in healthcare sectors to business and strategy development in the biopharma industry. This press relea

BioVentrix, Inc. , a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen to the Company’s board of directors. Mr. Cohen, an accredited public company director, has nearly 40 years of experience leading and guiding a variety of private and publicly traded life science companies as an

Expands pharmacy supply chain capabilities for efficient, compliant management of 340B programs Accelerates Omnicell’s strategic transformation to support the vision of the fully Autonomous Pharmacy, building on the recent launch of Omnicell One Expected to be immediately accretive to non-GAAP earnings per share MOUNTAIN VIEW, Calif.--( BUSINESS WIRE )-- Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solution

Helix BioPharma today announced that it has extended its collaboration agreement with Moffitt Cancer Center (“Moffitt”) for an additional year.

Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) is scheduled to participate in a virtual presentation and fireside chat at the August 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, August 19, 2020 at 4:00pm ET (1:00pm PT). A webcast of the presentation will be posted under the investor relations section of Aurora Spine’s website at www.aurora-spine.com , or can be accessed at https://www.

Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2020, and provided an overview of recent developments. “The second quarter was eventful for Atreca as we continue to execute on our vario

With strong momentum in its growing portfolio of life science companies, Paragon Biosciences announced the appointment of Kerensa Jimenez as the new chief executive officer of its capital markets group, Paragon Health Capital (PHC), a registered broker-dealer.

Ikena Oncology, a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies, today announced the publication in Nature Communications of a preclinical collaboration with the Jedd Wolchok and Taha Merghoub team at Memorial Sloan Kettering Cancer Center (MSK)